nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—hematologic cancer—muscle cancer	0.57	1	CtDrD
Lenalidomide—PTGS2—muscle cancer	0.226	1	CbGaD
Lenalidomide—PTGS2—Etoposide—muscle cancer	0.0297	0.368	CbGbCtD
Lenalidomide—ABCB1—Dactinomycin—muscle cancer	0.0174	0.215	CbGbCtD
Lenalidomide—ABCB1—Vincristine—muscle cancer	0.0107	0.132	CbGbCtD
Lenalidomide—ABCB1—Etoposide—muscle cancer	0.00981	0.121	CbGbCtD
Lenalidomide—TNFSF11—hindlimb—muscle cancer	0.00952	0.197	CbGeAlD
Lenalidomide—TNFSF11—appendage—muscle cancer	0.00816	0.169	CbGeAlD
Lenalidomide—ABCB1—Doxorubicin—muscle cancer	0.00669	0.0828	CbGbCtD
Lenalidomide—ABCB1—Methotrexate—muscle cancer	0.00648	0.0802	CbGbCtD
Lenalidomide—TNFSF11—embryo—muscle cancer	0.00271	0.0562	CbGeAlD
Lenalidomide—CDH5—embryo—muscle cancer	0.00204	0.0422	CbGeAlD
Lenalidomide—CDH5—smooth muscle tissue—muscle cancer	0.0016	0.0332	CbGeAlD
Lenalidomide—TNFSF11—tendon—muscle cancer	0.0016	0.0332	CbGeAlD
Lenalidomide—TNFSF11—bone marrow—muscle cancer	0.00155	0.0321	CbGeAlD
Lenalidomide—CDH5—cardiac atrium—muscle cancer	0.00138	0.0286	CbGeAlD
Lenalidomide—TNFSF11—head—muscle cancer	0.00137	0.0284	CbGeAlD
Lenalidomide—TNFSF11—testis—muscle cancer	0.00133	0.0275	CbGeAlD
Lenalidomide—CRBN—embryo—muscle cancer	0.0013	0.0268	CbGeAlD
Lenalidomide—PTGS2—hindlimb—muscle cancer	0.00124	0.0257	CbGeAlD
Lenalidomide—CDH5—tendon—muscle cancer	0.0012	0.025	CbGeAlD
Lenalidomide—CDH5—bone marrow—muscle cancer	0.00117	0.0242	CbGeAlD
Lenalidomide—CDH5—vagina—muscle cancer	0.00112	0.0232	CbGeAlD
Lenalidomide—PTGS2—appendage—muscle cancer	0.00106	0.022	CbGeAlD
Lenalidomide—Pomalidomide—PTGS2—muscle cancer	0.00105	0.608	CrCbGaD
Lenalidomide—CDH5—head—muscle cancer	0.00103	0.0214	CbGeAlD
Lenalidomide—CDH5—testis—muscle cancer	0.000998	0.0207	CbGeAlD
Lenalidomide—CRBN—renal system—muscle cancer	0.000981	0.0203	CbGeAlD
Lenalidomide—CRBN—cardiac atrium—muscle cancer	0.000878	0.0182	CbGeAlD
Lenalidomide—CRBN—tendon—muscle cancer	0.000765	0.0159	CbGeAlD
Lenalidomide—CRBN—bone marrow—muscle cancer	0.000741	0.0154	CbGeAlD
Lenalidomide—CRBN—vagina—muscle cancer	0.00071	0.0147	CbGeAlD
Lenalidomide—Thalidomide—PTGS2—muscle cancer	0.000676	0.392	CrCbGaD
Lenalidomide—CRBN—head—muscle cancer	0.000656	0.0136	CbGeAlD
Lenalidomide—CRBN—testis—muscle cancer	0.000634	0.0131	CbGeAlD
Lenalidomide—PTGS2—embryo—muscle cancer	0.000353	0.00731	CbGeAlD
Lenalidomide—PTGS2—smooth muscle tissue—muscle cancer	0.000277	0.00575	CbGeAlD
Lenalidomide—PTGS2—renal system—muscle cancer	0.000267	0.00553	CbGeAlD
Lenalidomide—ABCB1—embryo—muscle cancer	0.000218	0.00452	CbGeAlD
Lenalidomide—PTGS2—tendon—muscle cancer	0.000208	0.00432	CbGeAlD
Lenalidomide—PTGS2—bone marrow—muscle cancer	0.000202	0.00418	CbGeAlD
Lenalidomide—PTGS2—vagina—muscle cancer	0.000193	0.00401	CbGeAlD
Lenalidomide—PTGS2—head—muscle cancer	0.000179	0.0037	CbGeAlD
Lenalidomide—ABCB1—renal system—muscle cancer	0.000165	0.00342	CbGeAlD
Lenalidomide—ABCB1—bone marrow—muscle cancer	0.000125	0.00259	CbGeAlD
Lenalidomide—ABCB1—vagina—muscle cancer	0.00012	0.00248	CbGeAlD
Lenalidomide—ABCB1—head—muscle cancer	0.00011	0.00229	CbGeAlD
Lenalidomide—ABCB1—testis—muscle cancer	0.000107	0.00221	CbGeAlD
Lenalidomide—Skin disorder—Etoposide—muscle cancer	5.79e-05	0.000786	CcSEcCtD
Lenalidomide—Erectile dysfunction—Methotrexate—muscle cancer	5.78e-05	0.000785	CcSEcCtD
Lenalidomide—Dry skin—Doxorubicin—muscle cancer	5.76e-05	0.000783	CcSEcCtD
Lenalidomide—Hyperhidrosis—Etoposide—muscle cancer	5.76e-05	0.000782	CcSEcCtD
Lenalidomide—Abdominal pain upper—Doxorubicin—muscle cancer	5.74e-05	0.00078	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Methotrexate—muscle cancer	5.73e-05	0.000778	CcSEcCtD
Lenalidomide—Hypokalaemia—Doxorubicin—muscle cancer	5.72e-05	0.000777	CcSEcCtD
Lenalidomide—Breast disorder—Doxorubicin—muscle cancer	5.68e-05	0.000772	CcSEcCtD
Lenalidomide—Anorexia—Etoposide—muscle cancer	5.68e-05	0.000772	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	5.66e-05	0.000769	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	5.66e-05	0.000769	CcSEcCtD
Lenalidomide—Diarrhoea—Dactinomycin—muscle cancer	5.63e-05	0.000765	CcSEcCtD
Lenalidomide—Pneumonia—Methotrexate—muscle cancer	5.63e-05	0.000765	CcSEcCtD
Lenalidomide—Nasopharyngitis—Doxorubicin—muscle cancer	5.62e-05	0.000764	CcSEcCtD
Lenalidomide—Infestation NOS—Methotrexate—muscle cancer	5.59e-05	0.00076	CcSEcCtD
Lenalidomide—Infestation—Methotrexate—muscle cancer	5.59e-05	0.00076	CcSEcCtD
Lenalidomide—Depression—Methotrexate—muscle cancer	5.58e-05	0.000758	CcSEcCtD
Lenalidomide—Hypotension—Etoposide—muscle cancer	5.57e-05	0.000756	CcSEcCtD
Lenalidomide—Gastritis—Doxorubicin—muscle cancer	5.56e-05	0.000756	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Methotrexate—muscle cancer	5.55e-05	0.000754	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Doxorubicin—muscle cancer	5.54e-05	0.000753	CcSEcCtD
Lenalidomide—Muscular weakness—Doxorubicin—muscle cancer	5.54e-05	0.000753	CcSEcCtD
Lenalidomide—Renal failure—Methotrexate—muscle cancer	5.5e-05	0.000747	CcSEcCtD
Lenalidomide—Abdominal distension—Doxorubicin—muscle cancer	5.47e-05	0.000743	CcSEcCtD
Lenalidomide—Stomatitis—Methotrexate—muscle cancer	5.45e-05	0.000741	CcSEcCtD
Lenalidomide—Conjunctivitis—Methotrexate—muscle cancer	5.44e-05	0.000739	CcSEcCtD
Lenalidomide—Asthma—Doxorubicin—muscle cancer	5.43e-05	0.000738	CcSEcCtD
Lenalidomide—Influenza—Doxorubicin—muscle cancer	5.43e-05	0.000738	CcSEcCtD
Lenalidomide—Dysphagia—Doxorubicin—muscle cancer	5.43e-05	0.000738	CcSEcCtD
Lenalidomide—Hypersensitivity—Vincristine—muscle cancer	5.42e-05	0.000736	CcSEcCtD
Lenalidomide—Sweating—Methotrexate—muscle cancer	5.36e-05	0.000729	CcSEcCtD
Lenalidomide—Paraesthesia—Etoposide—muscle cancer	5.35e-05	0.000727	CcSEcCtD
Lenalidomide—Haematuria—Methotrexate—muscle cancer	5.33e-05	0.000725	CcSEcCtD
Lenalidomide—Pancreatitis—Doxorubicin—muscle cancer	5.33e-05	0.000724	CcSEcCtD
Lenalidomide—Dyspnoea—Etoposide—muscle cancer	5.31e-05	0.000722	CcSEcCtD
Lenalidomide—Somnolence—Etoposide—muscle cancer	5.29e-05	0.00072	CcSEcCtD
Lenalidomide—Angina pectoris—Doxorubicin—muscle cancer	5.29e-05	0.000719	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Methotrexate—muscle cancer	5.29e-05	0.000719	CcSEcCtD
Lenalidomide—Epistaxis—Methotrexate—muscle cancer	5.28e-05	0.000717	CcSEcCtD
Lenalidomide—Asthenia—Vincristine—muscle cancer	5.28e-05	0.000717	CcSEcCtD
Lenalidomide—Vomiting—Dactinomycin—muscle cancer	5.23e-05	0.000711	CcSEcCtD
Lenalidomide—Bronchitis—Doxorubicin—muscle cancer	5.22e-05	0.00071	CcSEcCtD
Lenalidomide—Agranulocytosis—Methotrexate—muscle cancer	5.22e-05	0.000709	CcSEcCtD
Lenalidomide—Rash—Dactinomycin—muscle cancer	5.19e-05	0.000705	CcSEcCtD
Lenalidomide—Decreased appetite—Etoposide—muscle cancer	5.18e-05	0.000704	CcSEcCtD
Lenalidomide—Pancytopenia—Doxorubicin—muscle cancer	5.16e-05	0.000701	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Etoposide—muscle cancer	5.14e-05	0.000699	CcSEcCtD
Lenalidomide—Fatigue—Etoposide—muscle cancer	5.13e-05	0.000698	CcSEcCtD
Lenalidomide—Pain—Etoposide—muscle cancer	5.09e-05	0.000692	CcSEcCtD
Lenalidomide—Constipation—Etoposide—muscle cancer	5.09e-05	0.000692	CcSEcCtD
Lenalidomide—Dysuria—Doxorubicin—muscle cancer	5.08e-05	0.00069	CcSEcCtD
Lenalidomide—Neutropenia—Doxorubicin—muscle cancer	5.08e-05	0.00069	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Doxorubicin—muscle cancer	5.05e-05	0.000686	CcSEcCtD
Lenalidomide—Haemoglobin—Methotrexate—muscle cancer	5.05e-05	0.000686	CcSEcCtD
Lenalidomide—Diarrhoea—Vincristine—muscle cancer	5.03e-05	0.000684	CcSEcCtD
Lenalidomide—Haemorrhage—Methotrexate—muscle cancer	5.02e-05	0.000682	CcSEcCtD
Lenalidomide—Hepatitis—Methotrexate—muscle cancer	5.02e-05	0.000682	CcSEcCtD
Lenalidomide—Pollakiuria—Doxorubicin—muscle cancer	5.02e-05	0.000682	CcSEcCtD
Lenalidomide—Pharyngitis—Methotrexate—muscle cancer	4.98e-05	0.000677	CcSEcCtD
Lenalidomide—Urinary tract disorder—Methotrexate—muscle cancer	4.96e-05	0.000674	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Doxorubicin—muscle cancer	4.96e-05	0.000674	CcSEcCtD
Lenalidomide—Weight increased—Doxorubicin—muscle cancer	4.94e-05	0.000672	CcSEcCtD
Lenalidomide—Urethral disorder—Methotrexate—muscle cancer	4.92e-05	0.000669	CcSEcCtD
Lenalidomide—Weight decreased—Doxorubicin—muscle cancer	4.91e-05	0.000668	CcSEcCtD
Lenalidomide—Feeling abnormal—Etoposide—muscle cancer	4.91e-05	0.000667	CcSEcCtD
Lenalidomide—Hyperglycaemia—Doxorubicin—muscle cancer	4.9e-05	0.000666	CcSEcCtD
Lenalidomide—Nausea—Dactinomycin—muscle cancer	4.89e-05	0.000664	CcSEcCtD
Lenalidomide—Pneumonia—Doxorubicin—muscle cancer	4.87e-05	0.000662	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Etoposide—muscle cancer	4.87e-05	0.000662	CcSEcCtD
Lenalidomide—Dizziness—Vincristine—muscle cancer	4.86e-05	0.000661	CcSEcCtD
Lenalidomide—Infestation NOS—Doxorubicin—muscle cancer	4.84e-05	0.000658	CcSEcCtD
Lenalidomide—Infestation—Doxorubicin—muscle cancer	4.84e-05	0.000658	CcSEcCtD
Lenalidomide—Visual impairment—Methotrexate—muscle cancer	4.84e-05	0.000658	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	4.8e-05	0.000653	CcSEcCtD
Lenalidomide—Renal failure—Doxorubicin—muscle cancer	4.76e-05	0.000647	CcSEcCtD
Lenalidomide—Erythema multiforme—Methotrexate—muscle cancer	4.75e-05	0.000645	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Doxorubicin—muscle cancer	4.75e-05	0.000645	CcSEcCtD
Lenalidomide—Urticaria—Etoposide—muscle cancer	4.73e-05	0.000643	CcSEcCtD
Lenalidomide—Stomatitis—Doxorubicin—muscle cancer	4.72e-05	0.000642	CcSEcCtD
Lenalidomide—Abdominal pain—Etoposide—muscle cancer	4.71e-05	0.00064	CcSEcCtD
Lenalidomide—Body temperature increased—Etoposide—muscle cancer	4.71e-05	0.00064	CcSEcCtD
Lenalidomide—Urinary tract infection—Doxorubicin—muscle cancer	4.71e-05	0.00064	CcSEcCtD
Lenalidomide—Conjunctivitis—Doxorubicin—muscle cancer	4.71e-05	0.00064	CcSEcCtD
Lenalidomide—Eye disorder—Methotrexate—muscle cancer	4.69e-05	0.000638	CcSEcCtD
Lenalidomide—Tinnitus—Methotrexate—muscle cancer	4.68e-05	0.000636	CcSEcCtD
Lenalidomide—Vomiting—Vincristine—muscle cancer	4.67e-05	0.000635	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—muscle cancer	4.66e-05	0.000633	CcSEcCtD
Lenalidomide—Sweating—Doxorubicin—muscle cancer	4.64e-05	0.000631	CcSEcCtD
Lenalidomide—Rash—Vincristine—muscle cancer	4.64e-05	0.00063	CcSEcCtD
Lenalidomide—Dermatitis—Vincristine—muscle cancer	4.63e-05	0.000629	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—muscle cancer	4.62e-05	0.000628	CcSEcCtD
Lenalidomide—Headache—Vincristine—muscle cancer	4.61e-05	0.000626	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Doxorubicin—muscle cancer	4.58e-05	0.000623	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—muscle cancer	4.57e-05	0.000621	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—muscle cancer	4.56e-05	0.000619	CcSEcCtD
Lenalidomide—Sinusitis—Doxorubicin—muscle cancer	4.54e-05	0.000618	CcSEcCtD
Lenalidomide—Immune system disorder—Methotrexate—muscle cancer	4.54e-05	0.000616	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—muscle cancer	4.53e-05	0.000615	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—muscle cancer	4.52e-05	0.000614	CcSEcCtD
Lenalidomide—Chills—Methotrexate—muscle cancer	4.51e-05	0.000612	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—muscle cancer	4.44e-05	0.000603	CcSEcCtD
Lenalidomide—Bradycardia—Doxorubicin—muscle cancer	4.43e-05	0.000602	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—muscle cancer	4.4e-05	0.000598	CcSEcCtD
Lenalidomide—Hypersensitivity—Etoposide—muscle cancer	4.39e-05	0.000596	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—muscle cancer	4.37e-05	0.000594	CcSEcCtD
Lenalidomide—Erythema—Methotrexate—muscle cancer	4.37e-05	0.000594	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—muscle cancer	4.37e-05	0.000594	CcSEcCtD
Lenalidomide—Nausea—Vincristine—muscle cancer	4.37e-05	0.000594	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—muscle cancer	4.36e-05	0.000592	CcSEcCtD
Lenalidomide—Haemorrhage—Doxorubicin—muscle cancer	4.35e-05	0.000591	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—muscle cancer	4.35e-05	0.000591	CcSEcCtD
Lenalidomide—Hypoaesthesia—Doxorubicin—muscle cancer	4.33e-05	0.000588	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—muscle cancer	4.32e-05	0.000586	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—muscle cancer	4.29e-05	0.000584	CcSEcCtD
Lenalidomide—Oedema peripheral—Doxorubicin—muscle cancer	4.28e-05	0.000582	CcSEcCtD
Lenalidomide—Dysgeusia—Methotrexate—muscle cancer	4.28e-05	0.000582	CcSEcCtD
Lenalidomide—Asthenia—Etoposide—muscle cancer	4.27e-05	0.000581	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—muscle cancer	4.27e-05	0.000581	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—muscle cancer	4.26e-05	0.000579	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—muscle cancer	4.23e-05	0.000575	CcSEcCtD
Lenalidomide—Pruritus—Etoposide—muscle cancer	4.21e-05	0.000573	CcSEcCtD
Lenalidomide—Visual impairment—Doxorubicin—muscle cancer	4.19e-05	0.000569	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—muscle cancer	4.12e-05	0.00056	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—muscle cancer	4.11e-05	0.000559	CcSEcCtD
Lenalidomide—Diarrhoea—Etoposide—muscle cancer	4.08e-05	0.000554	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—muscle cancer	4.06e-05	0.000552	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—muscle cancer	4.06e-05	0.000551	CcSEcCtD
Lenalidomide—Tinnitus—Doxorubicin—muscle cancer	4.05e-05	0.000551	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—muscle cancer	4.04e-05	0.000549	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—muscle cancer	4.04e-05	0.000548	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—muscle cancer	4.04e-05	0.000548	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—muscle cancer	3.94e-05	0.000536	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—muscle cancer	3.94e-05	0.000536	CcSEcCtD
Lenalidomide—Dizziness—Etoposide—muscle cancer	3.94e-05	0.000535	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—muscle cancer	3.93e-05	0.000534	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—muscle cancer	3.93e-05	0.000534	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—muscle cancer	3.92e-05	0.000533	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—muscle cancer	3.91e-05	0.000532	CcSEcCtD
Lenalidomide—Chills—Doxorubicin—muscle cancer	3.9e-05	0.00053	CcSEcCtD
Lenalidomide—Arrhythmia—Doxorubicin—muscle cancer	3.88e-05	0.000528	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—muscle cancer	3.84e-05	0.000522	CcSEcCtD
Lenalidomide—Cough—Methotrexate—muscle cancer	3.81e-05	0.000518	CcSEcCtD
Lenalidomide—Mental disorder—Doxorubicin—muscle cancer	3.81e-05	0.000518	CcSEcCtD
Lenalidomide—Vomiting—Etoposide—muscle cancer	3.79e-05	0.000515	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—muscle cancer	3.78e-05	0.000514	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—muscle cancer	3.78e-05	0.000514	CcSEcCtD
Lenalidomide—Rash—Etoposide—muscle cancer	3.76e-05	0.00051	CcSEcCtD
Lenalidomide—Dermatitis—Etoposide—muscle cancer	3.75e-05	0.00051	CcSEcCtD
Lenalidomide—Headache—Etoposide—muscle cancer	3.73e-05	0.000507	CcSEcCtD
Lenalidomide—Flatulence—Doxorubicin—muscle cancer	3.73e-05	0.000507	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—muscle cancer	3.72e-05	0.000506	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—muscle cancer	3.72e-05	0.000506	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—muscle cancer	3.72e-05	0.000506	CcSEcCtD
Lenalidomide—Tension—Doxorubicin—muscle cancer	3.71e-05	0.000505	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—muscle cancer	3.71e-05	0.000504	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	3.7e-05	0.000502	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—muscle cancer	3.68e-05	0.0005	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—muscle cancer	3.68e-05	0.0005	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—muscle cancer	3.66e-05	0.000498	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—muscle cancer	3.64e-05	0.000495	CcSEcCtD
Lenalidomide—Confusional state—Methotrexate—muscle cancer	3.6e-05	0.000489	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—muscle cancer	3.57e-05	0.000485	CcSEcCtD
Lenalidomide—Infection—Methotrexate—muscle cancer	3.54e-05	0.000482	CcSEcCtD
Lenalidomide—Nausea—Etoposide—muscle cancer	3.54e-05	0.000481	CcSEcCtD
Lenalidomide—Ill-defined disorder—Doxorubicin—muscle cancer	3.51e-05	0.000477	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—muscle cancer	3.5e-05	0.000475	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—muscle cancer	3.5e-05	0.000475	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—muscle cancer	3.49e-05	0.000475	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—muscle cancer	3.48e-05	0.000473	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—muscle cancer	3.47e-05	0.000471	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methotrexate—muscle cancer	3.45e-05	0.000469	CcSEcCtD
Lenalidomide—Malaise—Doxorubicin—muscle cancer	3.41e-05	0.000464	CcSEcCtD
Lenalidomide—Vertigo—Doxorubicin—muscle cancer	3.4e-05	0.000462	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—muscle cancer	3.4e-05	0.000462	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—muscle cancer	3.39e-05	0.000461	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—muscle cancer	3.39e-05	0.00046	CcSEcCtD
Lenalidomide—Palpitations—Doxorubicin—muscle cancer	3.34e-05	0.000455	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—muscle cancer	3.33e-05	0.000453	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—muscle cancer	3.33e-05	0.000452	CcSEcCtD
Lenalidomide—Cough—Doxorubicin—muscle cancer	3.3e-05	0.000449	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—muscle cancer	3.27e-05	0.000444	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—muscle cancer	3.25e-05	0.000442	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—muscle cancer	3.23e-05	0.000439	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—muscle cancer	3.22e-05	0.000438	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—muscle cancer	3.22e-05	0.000438	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—muscle cancer	3.22e-05	0.000438	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—muscle cancer	3.21e-05	0.000436	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—muscle cancer	3.2e-05	0.000435	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	3.2e-05	0.000435	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—muscle cancer	3.18e-05	0.000433	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—muscle cancer	3.18e-05	0.000432	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—muscle cancer	3.17e-05	0.000431	CcSEcCtD
Lenalidomide—Dry mouth—Doxorubicin—muscle cancer	3.15e-05	0.000428	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—muscle cancer	3.14e-05	0.000427	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—muscle cancer	3.11e-05	0.000423	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—muscle cancer	3.1e-05	0.000421	CcSEcCtD
Lenalidomide—Oedema—Doxorubicin—muscle cancer	3.09e-05	0.00042	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—muscle cancer	3.08e-05	0.000419	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—muscle cancer	3.08e-05	0.000418	CcSEcCtD
Lenalidomide—Infection—Doxorubicin—muscle cancer	3.07e-05	0.000417	CcSEcCtD
Lenalidomide—Pain—Methotrexate—muscle cancer	3.05e-05	0.000415	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—muscle cancer	3.04e-05	0.000413	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—muscle cancer	3.03e-05	0.000412	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—muscle cancer	3.02e-05	0.000411	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—muscle cancer	3.01e-05	0.00041	CcSEcCtD
Lenalidomide—Skin disorder—Doxorubicin—muscle cancer	3e-05	0.000408	CcSEcCtD
Lenalidomide—Hyperhidrosis—Doxorubicin—muscle cancer	2.99e-05	0.000406	CcSEcCtD
Lenalidomide—Anorexia—Doxorubicin—muscle cancer	2.94e-05	0.0004	CcSEcCtD
Lenalidomide—Feeling abnormal—Methotrexate—muscle cancer	2.94e-05	0.0004	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methotrexate—muscle cancer	2.92e-05	0.000396	CcSEcCtD
Lenalidomide—Hypotension—Doxorubicin—muscle cancer	2.89e-05	0.000392	CcSEcCtD
Lenalidomide—Urticaria—Methotrexate—muscle cancer	2.83e-05	0.000385	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—muscle cancer	2.82e-05	0.000383	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—muscle cancer	2.82e-05	0.000383	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	2.81e-05	0.000382	CcSEcCtD
Lenalidomide—Insomnia—Doxorubicin—muscle cancer	2.79e-05	0.00038	CcSEcCtD
Lenalidomide—Paraesthesia—Doxorubicin—muscle cancer	2.77e-05	0.000377	CcSEcCtD
Lenalidomide—Dyspnoea—Doxorubicin—muscle cancer	2.75e-05	0.000374	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—muscle cancer	2.75e-05	0.000373	CcSEcCtD
Lenalidomide—Dyspepsia—Doxorubicin—muscle cancer	2.72e-05	0.00037	CcSEcCtD
Lenalidomide—Decreased appetite—Doxorubicin—muscle cancer	2.69e-05	0.000365	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—muscle cancer	2.67e-05	0.000362	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—muscle cancer	2.66e-05	0.000362	CcSEcCtD
Lenalidomide—Pain—Doxorubicin—muscle cancer	2.64e-05	0.000359	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—muscle cancer	2.64e-05	0.000359	CcSEcCtD
Lenalidomide—Hypersensitivity—Methotrexate—muscle cancer	2.63e-05	0.000357	CcSEcCtD
Lenalidomide—Asthenia—Methotrexate—muscle cancer	2.56e-05	0.000348	CcSEcCtD
Lenalidomide—Feeling abnormal—Doxorubicin—muscle cancer	2.55e-05	0.000346	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Doxorubicin—muscle cancer	2.53e-05	0.000343	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—muscle cancer	2.52e-05	0.000343	CcSEcCtD
Lenalidomide—Urticaria—Doxorubicin—muscle cancer	2.45e-05	0.000334	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—muscle cancer	2.44e-05	0.000332	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—muscle cancer	2.44e-05	0.000332	CcSEcCtD
Lenalidomide—Diarrhoea—Methotrexate—muscle cancer	2.44e-05	0.000332	CcSEcCtD
Lenalidomide—Dizziness—Methotrexate—muscle cancer	2.36e-05	0.000321	CcSEcCtD
Lenalidomide—Hypersensitivity—Doxorubicin—muscle cancer	2.28e-05	0.000309	CcSEcCtD
Lenalidomide—Vomiting—Methotrexate—muscle cancer	2.27e-05	0.000308	CcSEcCtD
Lenalidomide—Rash—Methotrexate—muscle cancer	2.25e-05	0.000306	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—muscle cancer	2.25e-05	0.000305	CcSEcCtD
Lenalidomide—Headache—Methotrexate—muscle cancer	2.23e-05	0.000304	CcSEcCtD
Lenalidomide—Asthenia—Doxorubicin—muscle cancer	2.22e-05	0.000301	CcSEcCtD
Lenalidomide—Pruritus—Doxorubicin—muscle cancer	2.19e-05	0.000297	CcSEcCtD
Lenalidomide—Nausea—Methotrexate—muscle cancer	2.12e-05	0.000288	CcSEcCtD
Lenalidomide—Diarrhoea—Doxorubicin—muscle cancer	2.11e-05	0.000287	CcSEcCtD
Lenalidomide—Dizziness—Doxorubicin—muscle cancer	2.04e-05	0.000278	CcSEcCtD
Lenalidomide—Vomiting—Doxorubicin—muscle cancer	1.96e-05	0.000267	CcSEcCtD
Lenalidomide—Rash—Doxorubicin—muscle cancer	1.95e-05	0.000265	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—muscle cancer	1.95e-05	0.000264	CcSEcCtD
Lenalidomide—Headache—Doxorubicin—muscle cancer	1.94e-05	0.000263	CcSEcCtD
Lenalidomide—Nausea—Doxorubicin—muscle cancer	1.83e-05	0.000249	CcSEcCtD
